Centessa Pharmaceuticals Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Results: Net Loss Widens to $50.<a href="https://laohu8.com/S/MMM">3M</a>, Increased R&D Spending Highlights Focus on Orexin Agonist Pipeline
Centessa Pharmaceuticals plc has reported its financial results for the second quarter ending June 30, 2025. The company recorded a net loss of $50.3 million, an increase from the $43.8 million net loss in the same period of 2024. General and Administrative expenses rose to $11.9 million compared to $11.2 million the previous year, while Research and Development expenses increased significantly to $42.7 million from $32.8 million in the second quarter of 2024. Cash, cash equivalents, and investments totaled $404.1 million as of June 30, 2025, with the company projecting that these funds will support operations into mid-2027. Centessa Pharmaceuticals continues to advance its orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected within the year. This includes the ORX750 Phase 2a CRYSTAL-1 study for narcolepsy and idiopathic hypersomnia and the ORX142 Phase 1 trial for select neurological disorders. ORX489 remains in IND-enabling studies for neuropsychiatric disorders.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Centessa Pharmaceuticals plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001847903-25-000133), on August 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。